Session 3 : Infectious diseases

Human immunodeficiency virus type 1 (HIV-1) entry into target cells appears to be triggered when two heptad repeat regions in the ectodomain of gp41 associate, converting the prefusogenic form of gp41 to a fusogenic form. Peptides from these two heptad repeat regions, designated N51 and C43, form a coiled coil consisting of an ƒÁ-helical trimer of heterodimers which approximates the core of the fusogenic form of gp41. To understand the antigenic structure of gp41 in these two configurations, and to examine the specificity of antigp41 antibodies produced by HIV-1-infected individuals, human anti-gp41 monoclonal antibodies (mAbs) were tested for their reactivity against N51, C43, and the complex formed by these peptides. The human mAbs were generated via fusion of a heteromyeloma with EBV-transformed peripheral lymphocytes derived from HIV-1-infected individuals. Of 11 mAbs, 7 reacted with the complex but with neither of the parent peptides. These mAbs reacted optimally with the N51C43 complex prepared at a 1 : 1 ratio and appeared to recognize the fusogenic form of gp41 in which the two heptad repeat regions are associated to form coiled coil.The existence of antibodies from HIV-1-infected humans that exclusively recognize the N51-C43 complex constitutes the first proof that the coiled-coil conformation of gp41 exists in vivo and is immunogenic. Two of the 11 mAbs were specific for the hydrophilic loop region of gp41 and failed to react with either peptide alone or with the peptide complex, while the remaining 2 mAbs reacted with peptide C43. One of these two latter mAbs, 98-6, also reacted well with the equimolar N51-C43 complex, while reactivity with C43 by the other mAb, 2F5, was inhibited by even small amounts of N51, suggesting that the interaction of these peptides occludes or disrupts the epitope recognized by mAb 2F5. Mabs 98-6 and 2F5 are also unusual among the mAbs tested in their ability to neutralize multiple primary HIV isolates, although 2F5 displays more broad and potent activity. The data suggest that anti-gp41 neutralizing activity is associated with specificity for a region in C43 which participates in complex formation with N51. Serum Abs specific for C43 are present in all HIV-infected individuals, but Abs that inhibit the ability of N51 to complex with C43, a step which may block the infectious process, are present in less than 5% of patients’ sera. Characterization of the Abs with inhibitory activity may lead to design of immunogens corresponding to the C43 region that would be valuable for vaccine development.